| Regulatory reference: | FDA “guidelines for effectiveness testing of antiperspirant drug products”, CFR 21 protocol |
| Claim: | Anti-perspirant activity |
| Application field: | Active ingredients, mixtures or finished products. |
| Description of the test: | The test is carried out on 30 volunteers. Pre-treatment cycle of 17 days, treatment cycle with the anti-perspiration product for 4 days, exposure in acclimatized room for the times and in the conditions laid down according to the FDA normative at T 24 hours subsequently to the interruption of the anti-perspiration treatment. Gravimetrical reading with analytical balance at T 24 hours of the treated side against the high non-treated armpit. Report in English with Wilkoxon method statistical analysis. |